Adaptimmune Therapeutics plc (ADAP)
ADAP Stock Price Chart
Explore Adaptimmune Therapeutics plc interactive price chart. Choose custom timeframes to analyze ADAP price movements and trends.
ADAP Company Profile
Discover essential business fundamentals and corporate details for Adaptimmune Therapeutics plc (ADAP) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
6 May 2015
Employees
506.00
Website
https://www.adaptimmune.comCEO
Adrian G. Rawcliffe
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
ADAP Financial Timeline
Browse a chronological timeline of Adaptimmune Therapeutics plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.09, while revenue estimate is $12.31M.
Earnings released on 13 Aug 2025
EPS came in at -$0.11 surpassing the estimated -$0.15 by +26.67%, while revenue for the quarter reached $13.68M , beating expectations by +5.76%.
Earnings released on 13 May 2025
EPS came in at -$0.18 matching the estimated -$0.18, while revenue for the quarter reached $7.29M , missing expectations by -15.88%.
Earnings released on 24 Mar 2025
EPS came in at -$0.26 falling short of the estimated -$0.17 by -52.94%, while revenue for the quarter reached $3.22M , missing expectations by -61.73%.
Earnings released on 13 Nov 2024
EPS came in at -$0.07 surpassing the estimated -$0.17 by +58.82%, while revenue for the quarter reached $40.90M , beating expectations by +266.17%.
Earnings released on 12 Aug 2024
EPS came in at $0.24 surpassing the estimated -$0.07 by +442.86%, while revenue for the quarter reached $12.82M , beating expectations by +14.80%.
Earnings released on 15 May 2024
EPS came in at -$0.18 falling short of the estimated -$0.16 by -12.50%, while revenue for the quarter reached $5.68M , missing expectations by -47.08%.
Earnings released on 6 Mar 2024
EPS came in at -$0.24 falling short of the estimated -$0.12 by -100.00%, while revenue for the quarter reached $4.66M , missing expectations by -17.23%.
Earnings released on 8 Nov 2023
EPS came in at -$0.20 matching the estimated -$0.20, while revenue for the quarter reached $7.32M , missing expectations by -64.25%.
Earnings released on 9 Aug 2023
EPS came in at -$0.21 falling short of the estimated -$0.17 by -23.53%, while revenue for the quarter reached $5.13M , missing expectations by -50.10%.
Earnings released on 12 May 2023
EPS came in at $0.01 surpassing the estimated -$0.19 by +105.26%, while revenue for the quarter reached $4.76M , missing expectations by -3.45%.
Earnings released on 6 Mar 2023
EPS came in at -$0.18 surpassing the estimated -$0.25 by +28.00%, while revenue for the quarter reached $11.03M , beating expectations by +123.69%.
Earnings released on 8 Nov 2022
EPS came in at -$0.24 surpassing the estimated -$0.28 by +14.29%, while revenue for the quarter reached $7.01M , beating expectations by +1.13%.
Earnings released on 4 Aug 2022
EPS came in at -$0.28 matching the estimated -$0.28, while revenue for the quarter reached $5.54M , missing expectations by -15.73%.
Earnings released on 9 May 2022
EPS came in at -$0.32 falling short of the estimated -$0.26 by -23.08%, while revenue for the quarter reached $3.58M , beating expectations by +2.14%.
Earnings released on 14 Mar 2022
EPS came in at -$0.25 falling short of the estimated -$0.22 by -13.64%, while revenue for the quarter reached $1.42M , missing expectations by -68.51%.
Earnings released on 4 Nov 2021
EPS came in at -$0.27 matching the estimated -$0.27, while revenue for the quarter reached $1.20M , missing expectations by -12.19%.
Earnings released on 9 Aug 2021
EPS came in at -$0.24 surpassing the estimated -$0.25 by +4.00%, while revenue for the quarter reached $3.10M , meeting expectations.
Earnings released on 6 May 2021
EPS came in at -$0.24 surpassing the estimated -$0.25 by +4.00%, while revenue for the quarter reached $434.00K , missing expectations by -3.85%.
Earnings released on 25 Feb 2021
EPS came in at -$0.24 falling short of the estimated -$0.23 by -4.35%, while revenue for the quarter reached $1.50M , missing expectations by -24.14%.
Earnings released on 5 Nov 2020
EPS came in at -$0.23 matching the estimated -$0.23, while revenue for the quarter reached $1.19M , missing expectations by -4.00%.
ADAP Stock Performance
Access detailed ADAP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.